Please Wait.....
Report
Lung Cancer Therapeutics Market Report by Therapy (Targeted Therapy, Immunotherapy, Radiation Therapy, Chemotherapy), Cancer Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2023-2028
Market Report I 2023-09-04 I 145 Pages I IMARC Group
Market Overview:
The global lung cancer therapeutics market size reached US$ 27,221.60 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 50,233 Million by 2028, exhibiting a growth rate (CAGR) of 10.90% during 2023-2028. The rising prevalence of lung cancer due to unhealthy lifestyles and excessive smoking, increasing awareness among individuals about the importance of early diagnosis and treatment, and advancements in precision medicine represent some of the key factors driving the market.
Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.
Lung Cancer Therapeutics Market Trends:
The rising awareness among individuals about the benefits of early diagnosis and treatment of cancer currently represents one of the key factors offering a favorable market outlook. Apart from this, the development of targeted therapies that offer personalized treatment options and improve patient outcomes are favoring market growth. Molecular testing and genetic profiling enable the identification of specific mutations and biomarkers in lung cancer cells. In line with this, the increasing use of nanomedicine to increase the efficient delivery of the anticancer drug to the affected tissues by enhancing the efficacy and reducing the side effects. Furthermore, the increasing use of immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other therapies is creating a positive market outlook. Additionally, the rising adoption of combination therapies, which involve the simultaneous use of multiple treatment modalities, is strengthening the market growth. Besides this, the expanding utilization of liquid biopsies, which involve the analysis of circulating tumor deoxyribonucleic acid (DNA) and other biomarkers in blood samples, is driving the market. Liquid biopsies act as a non-invasive method of assessing tumor mutational status and treatment response, thereby enabling real-time monitoring and adjustment of therapy. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop innovative therapies and drugs are propelling market growth. Along with this, ongoing research and technological advancements in novel treatment modalities, drug delivery systems, and diagnostic tools for lung cancer are expected to stimulate market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global lung cancer therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on therapy, cancer type, and distribution channel.
Therapy Insights:
Targeted Therapy
Bevacizumab
Dabrafenib/Trametinib
Erlotinib Hydrochloride
Osimertinib
Others
Immunotherapy
Durvalumab
Nivolumab
Atezolizumab
Pembrolizumab
Radiation Therapy
External Beam
Internal Beam
Systemic
Chemotherapy
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.
Cancer Type Insights:
Non-small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.
Distribution Channel Insights:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.
Regional Insights:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for lung cancer therapeutics. Some of the factors driving the North America lung cancer therapeutics market included the increasing prevalence of lung cancer, rising awareness among individuals about the benefits of early diagnosis and treatment, technological advancements in treatment procedures, etc.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global lung cancer therapeutics market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
What are the key regional markets?
Which countries represent the most attractive lung cancer therapeutics market?
What is the breakup of the market based on the therapy?
Which is the most attractive therapy in the lung cancer therapeutics market?
What is the breakup of the market based on the cancer type?
Which is the most attractive cancer type in the lung cancer therapeutics market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the lung cancer therapeutics market?
What is the competitive structure of the global lung cancer therapeutics market?
Who are the key players/companies in the global lung cancer therapeutics market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Lung Cancer Therapeutics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapy
6.1 Targeted Therapy
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Bevacizumab
6.1.2.2 Dabrafenib/Trametinib
6.1.2.3 Erlotinib Hydrochloride
6.1.2.4 Osimertinib
6.1.2.4 Others
6.1.2 Market Forecast
6.2 Immunotherapy
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Durvalumab
6.2.2.2 Nivolumab
6.2.2.3 Atezolizumab
6.2.2.4 Pembrolizumab
6.2.2 Market Forecast
6.3 Radiation Therapy
6.3.1 Market Trends
6.3.2 Key Segment
6.3.2.1 External Beam
6.3.2.2 Internal Beam
6.3.2.3 Systemic
6.3.2 Market Forecast
6.4 Chemotherapy
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Cancer Type
7.1 Non-small Cell Lung Cancer (NSCLC)
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Small Cell Lung Cancer (SCLC)
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Amgen Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 AstraZeneca Plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Boehringer Ingelheim International GmbH
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Bristol-Myers Squibb Company
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Daiichi Sankyo Company Limited
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Eli Lilly and Company
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 GSK PLC
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Merck & Co. Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Novartis AG
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 Pfizer Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.12 Roche Holding AG
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.13 Takeda Pharmaceutical Company Limited
14.3.13.1 Company Overview
14.3.13.2 Product Portfolio
Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2022
Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2022
Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2022
Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2022
Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2022
Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis
Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2023-2028
Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
Table 7: Global: Lung Cancer Therapeutics Market: Key Players
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security